The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Subscribe To Our Newsletter & Stay Updated
